Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial

Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has generally been limited to immunomodulatory agents. Other options that complement the induction regimen with favorab...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Clin Oncol
Hoofdauteurs: Dimopoulos, Meletios A., Špička, Ivan, Quach, Hang, Oriol, Albert, Hájek, Roman, Garg, Mamta, Beksac, Meral, Bringhen, Sara, Katodritou, Eirini, Chng, Wee-Joo, Leleu, Xavier, Iida, Shinsuke, Mateos, María-Victoria, Morgan, Gareth, Vorog, Alexander, Labotka, Richard, Wang, Bingxia, Palumbo, Antonio, Lonial, Sagar
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Clinical Oncology 2020
Onderwerpen:
ORIGINAL REPORTS
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7768338/
https://ncbi.nlm.nih.gov/pubmed/33021870
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02060
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items